The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study

被引:2
作者
Kobayashi, Daiki [1 ,2 ,3 ]
Mizuno, Atsushi [4 ,5 ]
Shimbo, Takuro [6 ]
Aida, Azusa [7 ,8 ]
Noto, Hiroshi [8 ]
机构
[1] St Lukes Int Hosp, Div Gen Internal Med, Dept Med, Tokyo, Japan
[2] St Lukes Int Univ, Dept Epidemiol, Grad Sch Publ Hlth, Tokyo, Japan
[3] Fujita Med Univ, Toyoake, Aichi, Japan
[4] Juntendo Univ Hosp, Dept Cardiol, Tokyo, Japan
[5] St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan
[6] Ohta Nishinouchi Hosp, Dept Med, Koriyama, Fukushima, Japan
[7] Univ Tokyo, Grad Sch Med, Dept Diabet & Metab Dis, Tokyo, Japan
[8] St Lukes Int Hosp, Dept Endocrinol, Tokyo, Japan
关键词
Low LDL; Mortality; Cardiovascular disease; Longitudinal study; Dyslipidemia; LDL CHOLESTEROL; STATIN THERAPY; HEART-DISEASE; RISK; CORONARY; HYPERCHOLESTEROLEMIA; METAANALYSIS; PREVENTION; REDUCTION; EZETIMIBE;
D O I
10.1016/j.ijcard.2020.03.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: This study aimed to evaluate the association between very low levels of low-density lipoprotein (LDL) cholesterol and subsequent clinical outcomes among dyslipidemic patients. Methods: A retrospective longitudinal study was conducted at a large teaching hospital in Tokyo, Japan, from 2005 to 2018. We included all dyslipidemic adult patients who were followed up at the department of endocrinology. The primary outcome was all-cause mortality and the secondary outcome was cardiovascular disease. We compared the development of these outcomes according to LDL cholesterol categories through longitudinal analyses adjusting for potential confounders. Results: We included total of 4485 dyslipidemic patients. The mean patient age (standard deviation) was 58.4 (12.2) years, and 2286 patients were men. During a median follow-up of 5.3 (interquartile range 2.2-9.6) years, 252 (5.7%) patients died (25[0.6%] were cardiovascular deaths) and 912 (20.3%) patients developed cardiovascular diseases. Multivariable longitudinal analyses showed that the very low LDL cholesterol group (b60 mg/dl) had significantly higher all-cause mortality than the normal LDL cholesterol group (100-140 mg/ dl) (odds ratio[OR] 1.96, 95%confidence interval [CI]:1.22-3.16). Among high-risk patients for atherosclerotic cardiovascular disease (ASCVD), very low LDL cholesterol was significantly associated with increased all-cause mortality (OR 2.61, 95%CI: 1.12-6.10) but decreased incidence of cardiovascular disease (OR 0.47, 95%CI: 0.23-0.93). Conclusions: Very low LDL cholesterol is associated with increased all-causemortality but not statistically associated with cardiovascular disease incidence among dyslipidemic patients, regardless of risk. When patients were stratified according to ASCVD risk, this association was more obvious among high-risk patients. (c) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 103
页数:7
相关论文
共 34 条
  • [1] Ara R, 2008, HEALTH TECHNOL ASSES, V12, pIII
  • [2] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Baigent, Colin
    Landray, Martin J.
    Reith, Christina
    Emberson, Jonathan
    Wheeler, David C.
    Tomson, Charles
    Wanner, Christoph
    Krane, Vera
    Cass, Alan
    Craig, Jonathan
    Neal, Bruce
    Jiang, Lixin
    Hooi, Lai Seong
    Levin, Adeera
    Agodoa, Lawrence
    Gaziano, Mike
    Kasiske, Bertram
    Walker, Robert
    Massy, Ziad A.
    Feldt-Rasmussen, Bo
    Krairittichai, Udom
    Ophascharoensuk, Vuddidhej
    Fellstrom, Bengt
    Holdaas, Hallvard
    Tesar, Vladimir
    Wiecek, Andrzej
    Grobbee, Diederick
    de Zeeuw, Dick
    Gronhagen-Riska, Carola
    Dasgupta, Tanaji
    Lewis, David
    Herrington, William
    Mafham, Marion
    Majoni, William
    Wallendszus, Karl
    Grimm, Richard
    Pedersen, Terje
    Tobert, Jonathan
    Armitage, Jane
    Baxter, Alex
    Bray, Christopher
    Chen, Yiping
    Chen, Zhengming
    Hill, Michael
    Knott, Carol
    Parish, Sarah
    Simpson, David
    Sleight, Peter
    Young, Alan
    Collins, Rory
    [J]. LANCET, 2011, 377 (9784) : 2181 - 2192
  • [3] Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
    Barba, C
    Cavalli-Sforza, T
    Cutter, J
    Darnton-Hill, I
    Deurenberg, P
    Deurenberg-Yap, M
    Gill, T
    James, P
    Ko, G
    Miu, AH
    Kosulwat, V
    Kumanyika, S
    Kurpad, A
    Mascie-Taylor, N
    Moon, HK
    Nishida, C
    Noor, MI
    Reddy, KS
    Rush, E
    Schultz, JT
    Seidell, J
    Stevens, J
    Swinburn, B
    Tan, K
    Weisell, R
    Wu, ZS
    Yajnik, CS
    Yoshiike, N
    Zimmet, P
    [J]. LANCET, 2004, 363 (9403) : 157 - 163
  • [4] Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study
    Benn, Marianne
    Tybjaerg-Hansen, Anne
    Stender, Stefan
    Frikke-Schmidt, Ruth
    Nordestgaard, Borge G.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (06): : 508 - 519
  • [5] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [6] Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
    Casula, M.
    Mozzanica, F.
    Scotti, L.
    Tragni, E.
    Pirillo, A.
    Corrao, G.
    Catapano, A. L.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2017, 27 (05) : 396 - 406
  • [7] Catapano A.L., 2016, REV ESP CARDIOL ENGL, V70
  • [8] Statins for Prevention of Cardiovascular Disease in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force
    Chou, Roger
    Dana, Tracy
    Blazina, Ian
    Daeges, Monica
    Jeanne, Thomas L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19): : 2008 - 2024
  • [9] Dose-response analyses using restricted cubic spline functions in public health research
    Desquilbet, Loic
    Mariotti, Francois
    [J]. STATISTICS IN MEDICINE, 2010, 29 (09) : 1037 - 1057
  • [10] Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)
    Everett, Brendan M.
    Mora, Samia
    Glynn, Robert J.
    MacFadyen, Jean
    Ridker, Paul M.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (11) : 1682 - 1689